Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
It is developing the drug candidate to potentially treat immunological diseases
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
In clinical trials, treatment proved more effective than other therapies evaluated
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
Subscribe To Our Newsletter & Stay Updated
